FDA Chief Backs Streamlined Studies To Curb Drug Costs
U.S. Food and Drug Administration Commissioner Scott Gottlieb on Monday endorsed streamlined approaches to conducting clinical trials and evaluating their results, saying that drug development costs are on an "unsustainable path"...To view the full article, register now.
Already a subscriber? Click here to view full article